Ubrogepant: Mechanism of action, clinical and translational science by Ramesh Boinpally, Mohamad Shebley, Joel Trugman

Get full text

Atogepant: Mechanism of action, clinical and translational science by Ramesh Boinpally, Mohamad Shebley, Joel M. Trugman

Get full text

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women by Ahmed Nader, Nael M. Mostafa, Elaine Kim, Mohamad Shebley

Get full text

Mechanistic Modeling of Intra‐Tumor Spatial Distribution of Antibody‐Drug Conjugates: Insights into Dosing Strategies in Oncology by Jared Weddell, Manoj S. Chiney, Sumit Bhatnagar, John P. Gibbs, Mohamad Shebley

Get full text

Integrating real‐world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women by Denise Beck, Insa Winzenborg, Wei Gao, Nael M. Mostafa, Peter Noertersheuser, Stephanie E. Chiuve, Charlotte Owens, Mohamad Shebley

Get full text

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis by Sven Stodtmann, Ahmed Nader, Akshanth R. Polepally, Ahmed A. Suleiman, Insa Winzenborg, Peter Noertersheuser, Juki Ng, Nael M. Mostafa, Mohamad Shebley

Get full text

Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome by Michael C. Snabes, M.D., Ph.D., Juki Ng, Pharm.D., Ph.D., Hong Li, Ph.D., Izna Ali, Pharm.D., Ph.D., Mohamad Shebley, Ph.D., William D. Schlaff, M.D

Get full text

Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS‐CoV‐2 neutralizing monoclonal antibody ABBV‐47D11 in patients with COVID‐19 by Mohamad Shebley, Stanley Wang, Izna Ali, Preethi Krishnan, Rakesh Tripathi, Joseph M. Reardon, John Cafardi, Galia Rahav, Yoseph Caraco, Jihad Slim, Fadi Al Akhrass, Mengjia Yu, Yiran Hu, Rosa De Abreu Ferreira, Negar N. Alami

Get full text